Gavriel Mullokandov

Gavriel Mullokandov is currently a Biotechnology Analyst at Armistice Capital LLC, a New York-based hedge fund specializing in healthcare and consumer sectors. In this role, he focuses on analyzing biotechnology companies, conducting rigorous fundamental research, and supporting the fund’s investment strategies across public equity markets within the life sciences sector.

Prior to joining Armistice Capital in May 2022, Gavriel held the position of Analyst at Ghost Tree Capital LLC, where he similarly concentrated on biotechnology and healthcare investments. Before transitioning to the investment industry, he trained as a Clinical Pathology Resident and Physician Scientist at Weill Cornell Medicine, providing him with a deep understanding of clinical and scientific innovation relevant to the firms and therapeutic areas he analyzes.

Gavriel holds a B.A. in Biochemistry from Columbia College and earned his medical degree from the Icahn School of Medicine at Mount Sinai following earlier studies at Stuyvesant High School. His unique combined expertise in medicine and biochemistry, alongside his experience researching and investing in biotech equity opportunities, position him as a valued specialist in healthcare and biotechnology asset classes.